Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Inclusion Criteria

• •Histologically confirmed glioblastoma multiforme (GBM) or gliosarcoma
• •* Newly diagnosed by surgical biopsy or excision within the past 5 weeks
• •Supratentorial location, as determined by the following:
• •* Contrast-enhanced MRI performed preoperatively
• •* MRI performed postoperatively within 28 days prior to study entry (preferably within 72 hours of surgery)
• •* Postoperative scan not required if diagnosed by stereotactic biopsy and pre-operative MRI was performed
• •No gliomas graded \< GBM
• •No recurrent malignant gliomas
• •No tumor foci detected below the tentorium or beyond the cranial vault
• •No multifocal disease or leptomeningeal spread
• •Zubrod performance status 0-1
• •Neurologic function status 0-2
• •Absolute neutrophil count ≥ 1,800 cells/mm\^3
• •Platelet count ≥ 100,000 cells/mm\^3
• •Hemoglobin ≥ 8 g/dL (transfusion allowed)
• •BUN ≤ 25 mg/dL
• •Creatinine ≤ 1.5 mg/dL
• •Bilirubin ≤ 1.5 mg/dL
• •ALT or AST ≤ 2 times upper limit of normal
• •Fertile patients must use effective contraception during and for 2 months after completion of study treatment
• •Negative pregnancy test
• •Not pregnant or nursing
• •No prior invasive malignancies, except for nonmelanomatous skin cancer and carcinoma in situ of the uterine cervix or bladder, unless disease-free for ? 3 years
• •No severe, active comorbidity, defined as follows:
• •* Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
• •* Transmural myocardial infarction within the past 6 months
• •* Acute bacterial or fungal infection requiring intravenous antibiotics at study entry
• •* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to study entry
• •* Coagulation defects
• •* Known AIDS
• •No prior allergic reaction to the study drugs
• •No history of porphyria or G6PD deficiency
• •No allergy to gadolinium or contraindications to MRI
• •No other concurrent chemotherapy
• •Recovered from effects of surgery or postoperative infection and other complications
• •No prior systemic chemotherapy, including polifeprosan 20 with carmustine implant (Gliadel wafer), for the current GBM
• •* Prior chemotherapy for a different cancer allowed
• •No prior radiotherapy to the head and neck (except for T1 glottic cancer) that would result in overlap of radiation therapy fields
• •No prophylactic filgrastim (G-CSF) during the first course of study treatment
• •No concurrent sargramostim (GM-CSF)